Literature DB >> 24514082

Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.

Robert K Flamm1, Helio S Sader, David J Farrell, Ronald N Jones.   

Abstract

Streptococcus pneumoniae isolates (6,958) were collected from patients at 163 U.S. medical centers during 2009 through 2012. Isolates were evaluated for multidrug resistance (MDR) to penicillin, ceftriaxone, erythromycin, tetracycline, trimethoprim-sulfamethoxazole, and levofloxacin. Ceftaroline was 16-fold more potent than ceftriaxone (MIC50/MIC90, ≤0.25/2 μg/ml) against all isolates. For MDR isolates (35.2% of tested strains), ceftaroline (MIC50/MIC90, 0.06/0.25 μg/ml; 100.0% susceptible) was the most active agent tested, being 8-fold more potent than ceftriaxone (MIC50/MIC90, 0.5/2 μg/ml) and 16-fold more potent than penicillin (MIC50/MIC90, 1/4 μg/ml).

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24514082      PMCID： PMC4023719          DOI： 10.1128/AAC.02557-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009).

Authors:  Ronald N Jones; Helio S Sader; Gary J Moet; David J Farrell
Journal:  Diagn Microbiol Infect Dis       Date:  2010-11       Impact factor: 2.803

2.  In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.

Authors:  Céline Vidaillac; Steve N Leonard; Michael J Rybak
Journal:  Int J Antimicrob Agents       Date:  2010-03-26       Impact factor: 5.283

3.  Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.

Authors:  Ronald N Jones; David J Farrell; Rodrigo E Mendes; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2011-04       Impact factor: 5.790

Review 4.  Ceftaroline fosamil: a new broad-spectrum cephalosporin.

Authors:  Joseph B Laudano
Journal:  J Antimicrob Chemother       Date:  2011-04       Impact factor: 5.790

5.  Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).

Authors:  David J Farrell; Robert K Flamm; Ronald N Jones; Helio S Sader
Journal:  Diagn Microbiol Infect Dis       Date:  2012-11-10       Impact factor: 2.803

Review 6.  Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.

Authors:  Donald Biek; Ian A Critchley; Todd A Riccobene; Dirk A Thye
Journal:  J Antimicrob Chemother       Date:  2010-11       Impact factor: 5.790

7.  In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.

Authors:  Louis Saravolatz; Joan Pawlak; Leonard Johnson
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

8.  Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  K Kosowska-Shick; P L McGhee; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

9.  Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.

Authors:  Michael R Jacobs; Caryn E Good; Anne R Windau; Saralee Bajaksouzian; Donald Biek; Ian A Critchley; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

10.  In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.

Authors:  Lesley McGee; Donald Biek; Yigong Ge; Magderie Klugman; Mignon du Plessis; Anthony M Smith; Bernard Beall; Cynthia G Whitney; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191
View more
  6 in total

1.  Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.

Authors:  Helio S Sader; Robert K Flamm; Jennifer M Streit; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37.

Authors:  George Sakoulas; Poochit Nonejuie; Ravina Kullar; Joseph Pogliano; Michael J Rybak; Victor Nizet
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

3.  In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).

Authors:  Michael A Pfaller; Rodrigo E Mendes; Leonard R Duncan; Robert K Flamm; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

4.  Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

Authors:  Ronald N Jones; Jason E Schuchert; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 5.  Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application.

Authors:  Juwon Yim; Leah M Molloy; Jason G Newland
Journal:  Infect Dis Ther       Date:  2016-12-30

Review 6.  Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options.

Authors:  Alimuddin Zumla; Ziad A Memish; Markus Maeurer; Matthew Bates; Peter Mwaba; Jaffar A Al-Tawfiq; David W Denning; Frederick G Hayden; David S Hui
Journal:  Lancet Infect Dis       Date:  2014-09-01       Impact factor: 25.071
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.